or Try an Advanced Search...

    ETF Components for CNCR - Loncar Cancer Immunotherapy ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    GERN C 4.56 3.93
    ELVN C -0.69 3.15
    SMMT C -8.62 2.57
    NRIX C 2.54 2.29
    ITOS D 2.35 2.24
    NUVB D -1.68 2.15
    MRUS C -0.26 2.09
    BPMC B -1.21 1.92
    RVMD D -1.23 1.87
    ACRV F 0.99 1.76
    ERAS C -6.03 1.72
    REGN B -1.97 1.70
    MRK C -1.46 1.67
    JANX D -2.04 1.66
    PGEN C -1.34 1.64
    HCM D 1.74 1.61
    CGEM D 2.88 1.57
    EXEL C -0.86 1.55
    IMTX C -1.66 1.52
    DAWN F 0.30 1.51
    AURA F -3.50 1.51
    REPL D -3.35 1.49
    FHTX D 3.31 1.47
    TSVT F 3.89 1.47
    KURA D -2.53 1.45
    NUVL C -1.30 1.41
    SNDX D -2.81 1.39
    BCYC F -1.16 1.37
    TYRA D 1.62 1.35
    XNCR F 1.92 1.35
    BNTX F 1.40 1.34
    GMAB F 1.00 1.31
    PRLD F -2.95 1.28
    RCUS F -1.98 1.28
    YMAB D 0.09 1.27
    BMY F -0.96 1.23
    ACLX B 2.76 1.21
    IPHA D 4.37 1.21
    RLAY F -3.09 1.20
    KYMR D -0.20 1.19
    IDYA F -1.28 1.19
    SWTX D 0.03 1.18
    SDGR F -1.13 1.17
    KPTI F 3.53 1.13
    STRO F -2.70 1.13
    RXRX F 2.65 1.09
    LEGN C 2.62 1.05
    IGMS F 0.78 1.01
    ACET F -0.91 1.01
    RPTX F -1.85 1.00
    LYEL F 0.00 0.97
    VOR F 0.66 0.96
    AUTL F 3.25 0.91
    ARVN F -3.82 0.90
    IMCR F 3.51 0.87
    IOVA F -4.40 0.87
    GLUE F 8.36 0.86
    ALLO F -3.70 0.84
    IMRX F 3.67 0.76
    FATE F -1.86 0.70
    MRSN F -1.08 0.62
    GNLX F 12.28 0.55
    RAPT F -2.51 0.53
    CRBU F 0.00 0.49
    ZNTL F -2.52 0.46
    DNA F 8.37 0.45
    BMEA F -1.81 0.42
    MGNX F 2.44 0.40

    Represented by ETF Holdings

    Keywords: Cancer Biopharmaceutical Medicine Biotechnology Clinical Medicine Life Sciences Immunology Solid Tumors Antibodies Biology Immune System Cancer Treatment Drug Discovery Treatment Of Cancer Tyrosine Kinase Receptors Monoclonal Antibodies Oncology Disease Tumor Acute Myeloid Leukemia
    Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services Long-Term Care Facilities

    Recent News for Loncar Cancer Immunotherapy ETF & its Holdings

    Date Stock Title
    Jul 3 MRK Merck: Among The Best Health Care GARP Plays Today
    Jul 3 REGN Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
    Jul 3 KURA Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
    Jul 3 REGN Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
    Jul 3 BNTX GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
    Jul 3 REGN Sanofi, Regeneron win EU label expansion for Dupixent in COPD
    Jul 3 CRBU Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
    Jul 3 REGN Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
    Jul 3 RXRX Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
    Jul 2 REGN Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
    Jul 2 TYRA Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
    Jul 2 IOVA Unveiling Three US Growth Companies With High Insider Ownership
    Jul 2 NRIX Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional investors who own 66%
    Jul 2 MRK mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
    Jul 2 LEGN Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
    Jul 2 BNTX Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling
    Jul 2 LEGN J&J says Carvykti beat standard drugs in late-stage blood cancer trial
    Jul 2 REGN Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
    Jul 2 LEGN Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
    Jul 2 MRK N-Power Medicine partners with MSD to expand access to oncology clinical trials
    ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.
    Exchange Traded Fund ETF Exchange Traded Funds Biotechnology SPDR Cancer Betashares Immune System Immunotherapy Cancer Immunotherapy Biotechnology Sectors Lonca
    Back to the Main CNCR Page...